Alcon partners with NFL star Cooper Kupp on eye allergy campaign

Article

The new partnership supports Alcon's Pataday Once Daily Relief Extra Strength eye drops as treatment for eye allergies.

Alcon and Cooper Kupp, a wide receiver on the NFL's Los Angeles Rams team, have partnered on a new campaign spotlighting eye allergy treatment, the company announced Monday.

Cooper Kupp

Image courtesy of @cooperkupp via Instagram


The partnership supports Alcon's Pataday Once Daily Relief Extra Strength, which is the first 24-hour allergy itch relief eye drop available in the US without a prescription.

Kupp will participate in the "The Right Tool for the Job" full-scale media campaign, which will highlight his personal history of eye allergy symptoms and seeking relief treatment with Alcon's product, as well as encourage consumers to use the drops for their own eyeallergy relief.

Alcon's Pataday Once Daily Relief Extra Strength

Image courtesy of Alcon

In a statement, he shared how seasonal allergy flare ups and pollen have often lead to him suffering from itchy eyes—a distraction during training camp and on the field during games. The drops have since allowed him to control his symptoms.

As an antihistamine eye drop, Pataday works by offering fast and long-lasting allergy itch relief to those experiencing allergic conjunctivits, according to the company.

Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.